肿瘤抗体治疗的历史回顾与展望

A review of monoclonal antibody therapy for cancer and prospects

单克隆抗体作为一种靶向药物在肿瘤治疗中取得成功,目前抗体及其相关制品已成为发展最快的一类生物药。美国FDA至今已批准了40余个治疗性抗体,其中一半用于治疗肿瘤。近几年,新一代抗体药物,包括人源抗体、去糖基化抗体、双特异性抗体、抗体-药物偶联物和阻断免疫检查点抗体已成功用于肿瘤治疗。本文对抗体用于肿瘤治疗的历史、抗肿瘤抗体的发展概况和展望进行综述。

As a targeted drug,monoclonal antibodies have been successful in tumor therapy.Thus,antibodies and related products are the fastest-developing biological agents. There are currently more than 40 monoclonal antibodies in the market that have been approved by the FDA,half of which are used to treat cancer. In recent years,a new generation of antibody drugs,such as human antibody,glyco-engineered antibody,bispecific antibody,antibody-drug conjugates and immune checkpoint blockade antibody,have successfully cured various malignant tumors. In this paper,the history of antibody treatment for cancer,and the development and prospect of anti- tumor antibodies have been reviewed.